Standex International Corporation — Form 10-Q Summary
Reporting period: The filing covers the quarter and nine months ended March 31, 2023, Standex’s fiscal third quarter and first nine months of fiscal 2023. Comparisons are with the corresponding 2022 periods. The unaudited interim results are not necessarily indicative of full-year results.
Business context and key financial metrics
Standex is a diversified industrial manufacturer with five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. Unless otherwise noted, amounts below are in millions of dollars.
| Metric | Q3 FY2023 | Q3 FY2022 | Nine months FY2023 | Nine months FY2022 |
|---|---|---|---|---|
| Net sales | $184.3 | $189.3 | $552.7 | $550.6 |
| Gross profit | $70.9 | $68.4 | $211.5 | $203.4 |
| Gross margin | 38.5% | 36.1% | 38.3% | 36.9% |
| Income from operations | $88.5 | $24.5 | $142.6 | $69.1 |
| Net income | $80.5 | $17.3 | $118.8 | $48.1 |
| Diluted EPS | $6.77 | $1.34 | $9.97 | $3.97 |
| Operating cash flow, continuing operations | Not presented separately for quarter | Not presented separately for quarter | $50.4 | $48.6 |
Reported operating income and earnings include a $62.1 million pretax gain from the Procon business sale; the reported increases therefore do not represent recurring operating growth. The filing does not provide a single adjusted operating-income or adjusted EPS figure excluding this gain.
- Liquidity and debt: At March 31, 2023, cash was $175.3 million and funded debt was $175.0 million ($173.3 million carrying value after issuance costs), leaving approximately $2.0 million of net cash using carrying-value debt. Current assets were $460.8 million and current liabilities were $130.6 million.
- Credit availability: Standex renewed its revolving credit agreement for five years. The facility has a $500 million borrowing limit, with a conditional increase option of up to $250 million. After outstanding letters of credit, $343.7 million was available to borrow. The company reported covenant compliance, a 0.89 leverage ratio, and an 18.59 interest coverage ratio.
- Interest exposure: $175 million of debt was covered by floating-to-fixed swaps; the swaps converted the borrowing rate to a weighted average 1.14% base rate. The effective borrowing rate, including swaps, was 2.83%.
- Cash deployment: Nine-month investing cash flow was $49.1 million, including $67.0 million of Procon sale proceeds and $16.6 million of capital expenditures. Financing cash outflow was $30.0 million, including $18.6 million of treasury-stock purchases and $9.7 million of dividends. Cash increased $70.4 million from fiscal year-end.
Material changes versus the prior comparable periods
- Q3 sales declined 2.6%; organic sales grew 1.5%, offset by $4.7 million of unfavorable foreign exchange and $3.1 million from divestitures. Nine-month sales increased 0.4%; organic growth of 4.7% and acquisitions were largely offset by foreign exchange and divestitures.
- Gross margin improved 2.4 percentage points in Q3 and 1.4 points for the nine-month period. Management attributed improvement to pricing and productivity, which more than offset material and labor inflation; the nine-month comparison also benefited from the absence of a prior-year Engineering Technologies project charge.
- Q3 operating income rose to $88.5 million, primarily because of the Procon gain. Excluding the gain, reported operating income would have been approximately $26.4 million, compared with $24.5 million a year earlier; this is a simple subtraction, not a company-reported adjusted measure.
- Nine-month continuing-operations operating cash flow increased to $50.4 million from $48.6 million, despite $36.3 million used for working capital and other balance-sheet increases.
- Segment trends were mixed: nine-month sales declined 13.0% in Scientific and 2.7% in Electronics, while Specialty Solutions rose 15.6%, Engineering Technologies 4.7%, and Engraving 0.5%. Specialty Solutions’ operating income rose sharply, partly reflecting stronger sales and productivity, as well as comparison with prior-year labor stoppages.
Outlook, management commentary, risks, and unusual items
- Outlook: Management expected year-over-year improvement in key financial metrics for the remainder of fiscal 2023, supported by orders and productivity initiatives; it did not provide numerical full-year revenue or earnings guidance in this filing. For Q4, management expected similar revenue and margins in Electronics; similar to slightly higher revenue and margin in Engraving and Scientific; a moderate increase in Engineering Technologies; and a moderate-to-significant sequential revenue decline in Specialty Solutions, partly due to the Procon divestiture and lower Display Merchandising sales.
- Demand commentary: Management cited opportunities in electric vehicles, industrial applications, renewable energy, commercial aviation and defense. It expected lower vaccine-storage demand, while research and academic demand was improving. It also described supply constraints, labor shortages, inflation, and a slower recovery in China and Europe.
- Procon divestiture: The business was sold on February 28, 2023. Standex reported $67.0 million of cash proceeds at closing, excluding escrow amounts and net of closing cash, and a $62.1 million pretax gain. MD&A also describes the transaction as a $75 million sale. Procon’s results remain in continuing operations. Management said proceeds would support organic and inorganic investment and shareholder returns.
- Tax and other unusual items: Effective tax rates were 6.7% for Q3 and 13.0% for nine months, versus 24.0% and 24.5%. The lower rates reflected discrete tax items, including a benefit related to capital-loss carryforwards used against the Procon gain, R&D tax-credit adjustments, and other jurisdictional effects.
- Restructuring: Costs were $2.2 million in Q3 and $3.3 million for nine months. The company expected approximately $0.8 million more in fiscal 2023; current initiatives were expected to conclude by fiscal 2024.
- Risks and contingencies: The filing identifies exposure to economic and end-market conditions, customer delays, supply shortages, labor availability, inflation and raw-material costs, foreign exchange, and successful execution of restructuring and acquisition plans. Management did not expect existing legal matters to materially affect financial position, results, or cash flow; a previously accrued $5.7 million litigation settlement was paid and considered settled.
- Other: $98.8 million of cash was held by foreign subsidiaries; Standex expected to repatriate $30–$35 million during fiscal 2023 and noted possible tax or capital-control consequences. Disclosure controls were deemed effective, with no material change in internal control over financial reporting reported.
Most important facts for investors to verify
- How much of the reported earnings increase is attributable to the one-time $62.1 million Procon gain, and what recurring operating performance looks like by segment.
- The Procon transaction economics: MD&A’s stated $75 million sale description versus $67.0 million of cash proceeds reported at closing, including escrow, closing-cash, and other adjustments.
- Whether organic sales, margins, and backlog convert into revenue and cash flow, particularly given total backlog under one year fell 0.9% year over year to $264.5 million.
- Progress on cost-reduction initiatives and the expected $0.8 million remaining fiscal 2023 restructuring cost, alongside continued inflation, labor, and supply-chain pressures.
- Availability and cost of liquidity, including credit-facility covenants, variable-rate exposure after swaps, foreign cash repatriation, and pension funding; management estimated $7.4 million of U.S. funded-plan contributions in fiscal 2024.